AARD Falls 6.6% After Class Action Lead Plaintiff Notice

Aardvark Therapeutics, Inc. (AARD) fell 6.6% on Aug 26, 2026 after a notice highlighted a pending securities class action and the opportunity for investors with substantial losses to seek lead-plaintiff status.

What Aardvark announced

The announcement was a legal/regulatory update centered on a pending securities class action lawsuit involving Aardvark Therapeutics.

The notice says investors who purchased or acquired Aardvark common stock pursuant to, and/or traceable to, offering documents tied to the company’s initial public offering are part of the group at issue.

According to the allegations summarized in the notice, the complaint claims the offering documents and defendants failed to disclose certain information, including unexpected, reversible cardiac observations (such as QRS prolongation) seen in trials at above-target doses.

The notice also points to allegations that Aardvark’s clinical, regulatory, and commercial prospects — including the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and an open-label extension (OLE) — were materially overstated.

What it means for Aardvark

A class action process can keep a spotlight on a company’s disclosures, especially when the allegations are tied to clinical-trial safety observations and how they were communicated.

If the claims gain traction, the situation could raise questions about how investors should interpret the company’s prior messaging around its program and trials referenced in the notice, including HERO and the OLE.

Even without a final outcome, legal proceedings can become an ongoing overhang: they can consume management attention and keep uncertainty elevated around the company’s clinical and regulatory narrative.

How the stock reacted

AARD sold off quickly and stayed lower through the session.

Window	Move
5 min	-9.5%
10 min	-10.2%
30 min	-4.2%
1 hour	-13.9%
end of day	-6.6%

Versus the broader market, AARD underperformed by 6.9% on the day.